Equities

4Basebio PLC

4BB:LSE

4Basebio PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,145.00
  • Today's Change55.00 / 5.05%
  • Shares traded2.39k
  • 1 Year change86.18%
  • Beta--
Data delayed at least 20 minutes, as of May 09 2024 16:01 BST.
More ▼

Profile data is unavailable for this security.

About the company

4basebio PLC is a United Kingdom-based specialist life sciences company. It is focused on therapeutic deoxyribonucleic (DNA) for cell and gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. It is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads. It has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications. Its applications include AAV and Lentivirus viral vectors; mRNA vaccines and therapeutics, Genome editing; DNA vaccines, and Hermes non-viral delivery. It is also focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines.

  • Revenue in GBP (TTM)354.00k
  • Net income in GBP-6.28m
  • Incorporated2020
  • Employees--
  • Location
    4Basebio PLC25 Norman Way, OverCAMBRIDGE CB24 5QEUnited KingdomGBR
  • Phone+44 12 2396 7943
  • Websitehttps://www.4basebio.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Poolbeg Pharma PLC0.00-3.93m70.25m12.0070.25m12.00
Eco Animal Health Group Plc88.46m-1.62m81.29m228.0081.29m228.00
Scancell Holdings Plc0.00-11.32m91.64m51.0091.64m51.00
Faron Pharmaceuticals Oy0.00-26.61m111.61m34.00111.61m34.00
Futura Medical PLC3.10m-6.51m122.69m12.00122.69m12.00
Animalcare Group Plc74.35m1.20m136.45m220.00136.45m220.00
4Basebio PLC354.00k-6.28m139.58m--139.58m--
Allergy Therapeutics plc53.26m-50.22m157.29m635.00157.29m635.00
Alliance Pharma plc170.05m-7.06m158.61m249.00158.61m249.00
Avacta Group Plc16.03m-42.08m160.49m120.00160.49m120.00
hVIVO PLC56.04m16.12m190.50m274.00190.50m274.00
Data as of May 09 2024. Currency figures normalised to 4Basebio PLC's reporting currency: UK Pound GBX

Institutional shareholders

1.70%Per cent of shares held by top holders
HolderShares% Held
Aramea Asset Management AGas of 30 Jun 2022143.33k1.12%
Deutsche Bank AG (Private Banking Germany)as of 29 Feb 202451.67k0.40%
DWS Investment GmbHas of 31 Jan 202423.36k0.18%
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.